Evidence mapPaperPMID 33906835Full record

SynthesisBMJ open diabetes research & care2021

Association between varying cut-points of intermediate hyperglycemia and risk of mortality, cardiovascular events and chronic kidney disease: a systematic review and meta-analysis.

Unjali P Gujral, Ram Jagannathan, Siran He, Minxuan Huang, Lisa R Staimez, Jingkai Wei, Nanki Singh, K M Venkat Narayan

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in BMJ open diabetes research & care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis.American journal of preventive medicine · 2022 · on this map
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Meta-Analysis of the Effect of Metformin on the Progression of Different Types of Prediabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Continuous Glucose Monitoring for Prediabetes: What Are the Best Metrics?Journal of diabetes science and technology · 2024
    Review
  17. Article
  18. Article
  19. Article
  20. Modern-Day Management of the Dysglycemic Continuum: An Expert Viewpoint from the Arabian Gulf.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Unjali P GujralRollins School of Public Health, Hubert Department of Global Health, Emory University, Atlanta, Georgia, USA ugujral@emory.edu.ORCID 0000-0002-0352-813X
Ram JagannathanDivisoin of Hospital Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Siran HeDepartment of Nutrition and Health Sciences, Laney Graduate School, Emory University, Atlanta, Georgia, USA.
Minxuan HuangRollins School of Public Health, Department of Epdemiology, Emory University, Atlanta, Georgia, USA.
Lisa R StaimezRollins School of Public Health, Hubert Department of Global Health, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-2818-1187
Jingkai WeiDepartment of Epidemiology and Biostatistics, George Washington University School of Public Health and Health Services, Washington, District of Columbia, USA.
Nanki SinghDepartment of Political Science, Duke University, Durham, North Carolina, USA.
K M Venkat NarayanRollins School of Public Health, Hubert Department of Global Health, Emory University, Atlanta, Georgia, USA.ORCID 0000-0001-8621-5405

Funding

Georgia Clinical & Translational Science Alliance (Georgia CTSA)UL1TR002378 · EMORY UNIVERSITY · 2025 to 2025
$9.3M
Institutional Career Development CoreKL2TR002381 · EMORY UNIVERSITY · 2025 to 2025
$1.5M
Emory Specialized Center of Research Excellence (SCORE) on Sex DifferencesU54AG062334 · EMORY UNIVERSITY · 2025 to 2025
$1.5M
Technologies Advancing Translation - Regional CoreP30DK111024 · EMORY UNIVERSITY · 2025 to 2025
$775k
NCATS NIH HHS KL2 TR002381NCATS NIH HHS UL1 TR002378NHLBI NIH HHS R01 HL125442NIA NIH HHS U54 AG062334NIDDK NIH HHS P30 DK111024
6 · The paper itself

Abstract

introductionWe conducted a systematic review and meta-analysis to evaluate the updated evidence regarding prediabetes for predicting mortality, macrovascular and microvascular outcomes. RESEARCH DESIGN AND

methodsWe identified English language studies from MEDLINE, PubMed, OVID and Cochrane database indexed from inception to January 31, 2020. Paired reviewers independently identified 106 prospective studies, comprising nearly 1.85 million people, from 27 countries. Primary outcomes were all-cause mortality (ACM), cardiovascular mortality (CVDM), cardiovascular disease (CVD), coronary heart disease (CHD) and stroke. Secondary outcomes were heart failure, chronic kidney disease (CKD) and retinopathy.

resultsImpaired glucose tolerance was associated with ACM; HR 1.19, 95% CI (1.15 to 1.24), CVDM; HR 1.21, 95% CI (1.10 to 1.32), CVD; HR 1.18, 95% CI (1.11 to 1.26), CHD; HR; 1.13, 95% CI (1.05 to 1.21) and stroke; HR 1.24, 95% CI (1.06 to 1.45). Impaired fasting glucose (IFG) 110-125 mg/dL was associated with ACM; HR 1.17, 95% CI (1.13 to 1.22), CVDM; HR 1.20, 95% CI (1.09 to 1.33), CVD; HR 1.21, 95% CI (1.09 to 1.33), CHD; HR; 1.14, 95% CI (1.06 to 1.22) and stroke; HR 1.22, 95% CI (1.07 to 1.40). IFG 100-125 mg/dL was associated with ACM; HR 1.11, 95% CI (1.04 to 1.19), CVDM; HR 1.14, 95% CI (1.03 to 1.25), CVD; HR 1.15, 95% CI (1.05 to 1.25), CHD HR; 1.10, 95% CI (1.02 to 1.19) and CKD; HR; 1.09, 95% CI (1.01 to 1.18). Glycosylated hemoglobin A1c (HbA1c) 6.0%-6.4% was associated with ACM; HR 1.30, 95% CI (1.03 to 1.66), CVD; HR 1.32, 95% CI (1.00 to 1.73) and CKD; HR 1.50, 95% CI (1.32 to 1.70). HbA1c 5.7%-6.4% was associated with CVD HR 1.15, 95% CI (1.02 to 1.30), CHD; HR 1.28, 95% CI (1.13 to 1.46), stroke; HR 1.23, 95% CI (1.04 to 1.46) and CKD; HR 1.32, 95% CI (1.16 to 1.50).

conclusionPrediabetes is an elevated risk state for macrovascular and microvascular outcomes. The prevention and management of prediabetes should be considered.

Indexed as

Cardiovascular DiseasesHyperglycemiaPrediabetic StateRenal Insufficiency, ChronicHumansProspective Studiescomorbiditymortalityprediabetic state

Identifiers

PMID33906835
PMCPMC8088253

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.